How to Rapidly Determine First-in-Children Dosing for COVID-19 Therapeutics | Infectious Diseases | JAMA Pediatrics | JAMA Network
[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 6,365
Citations 0
Editorial
June 5, 2020

How to Rapidly Determine First-in-Children Dosing for COVID-19 Therapeutics

Author Affiliations
  • 1Division of Clinical Pharmacology, University of Utah, Salt Lake City
  • 2Division of Critical Care, Department of Pediatrics, University of Utah, Salt Lake City
JAMA Pediatr. 2020;174(10):e202435. doi:10.1001/jamapediatrics.2020.2435

Multiple drugs to treat coronavirus disease 2019 (COVID-19) are currently under investigation. As of May 1, 2020, ClinicalTrials.gov lists 409 active studies evaluating various therapeutics to treat COVID-19. Most of these studies enroll exclusively adults, providing limited data on children. However, if efficacy of COVID-19 therapeutics is established in adults, these drugs will also be widely prescribed to children for whom appropriate dosing has not been established. We know from observational studies across multiple therapeutics that inappropriate drug dosing places children at risk for treatment failure, toxicities, and even death.1

Dosing of drugs is different in children compared with adults primarily owing to age-related changes in anatomy and physiology, such as tissue composition, relative organ weight, blood flow rates, and the maturity of clearance processes, such as kidney and enzymatic function.2 Many of these processes mature nonlinearly, limiting direct weight-based extrapolations from adults to children.2

To determine optimal dosing in children, dedicated pediatric pharmacokinetic trials are needed.3 Despite an increase in pediatric drug trials, owing in large part to the Best Pharmaceuticals for Children Act and research consortiums such as the Pediatric Trials Network, pediatric drugs trials remain challenging. Pediatric trials are hampered by low study consent rates, difficulty in obtaining blood, limited blood volume available for biologic specimens, and heterogeneity in drug exposure across the age range. As a result, pediatric pharmacokinetic trials take significant time and resources. A 2019 analysis of pediatric drug trials submitted to the US Food and Drug Administration found that only 55.9% of pharmacokinetic studies were completed within 5 years.4 During a rapidly evolving pandemic, we urgently need a more efficient approach to determine rational dosing of established therapeutics for children affected by COVID-19.

In the absence of lengthy pediatric pharmacokinetic trials, modeling and simulation can leverage existing data to determine first-in-pediatric dosing in the face of urgent need.3,5-7 Broadly, pharmacokinetic models use mathematical equations to characterize drug disposition in the body. The processes that govern drug disposition in children can be built into the model (eg, maturation function that reflects age-related change in glomerular filtration). Once a model is established, simulation is used to predict concentrations for various dosing regimens, usually in a large number of simulated individuals reflecting population variability. Based on the population variability, these simulations will generate a range of exposures for each dosing regimen. If a specific concentration (eg, trough) or exposure (eg, area under the curve) is associated with efficacy or toxicity, the simulation results can estimate the number of children who would achieve the target concentration or remain below a toxic threshold for a given dose. Based on the risk-benefit balance for a particular therapeutic, an optimal dosing regimen across the pediatric age spectrum can be determined.

In this issue of JAMA Pediatrics, Maharaj et al8 use modeling and simulation to determine optimal dosing regimens for hydroxychloroquine and remdesivir in children with COVID-19. The authors used different modeling and simulation approaches for each drug based on the data available to build the models. For hydroxychloroquine, they used a physiologically based pharmacokinetic approach; for remdesivir, they scaled an adult-population pharmacokinetic model to children using allometry with age-dependent exponents. In both cases, they were able to establish pediatric dosing that achieved drug exposures that were comparable with the exposures achieved with standard adult dosing.

The axiom attributed to George Box that all models are wrong but that some are useful highlights the need to understand a model’s assumptions and limitations. Both of the modeling approaches used in the study (population pharmacokinetic and physiologically based pharmacokinetic) have strengths and limitations that are well described.9 Regardless of the technical approach, for modeling and simulation to be effective in determining first-in-pediatric dosing, there must be an established target drug exposure. Often, this is simply matching the simulated pediatric exposure with the exposure observed in the adult efficacy trial. In other instances, there is an effective concentration identified through in vitro studies. In the current study, Maharaj et al8 highlight the challenges in these assumptions. For hydroxychloroquine, they used the pediatric model to match the exposure following a standard dosing regimen in adults (400 mg twice a day for 1 day or 200 mg twice a day for 4 days). However, these matched exposures resulted in concentrations below the threshold needed for viral suppression that was identified in an in vitro study.10 Although hydroxychloroquine may have an additional immunomodulatory effect, these results suggest that hydroxychloroquine dosing recommendations for both adults and children may be inadequate to achieve appropriate viral suppression.

Mathematical equations by themselves cannot replace prospective clinical trials. Once model-based recommendations are made, they will need to be evaluated. One innovative approach to collecting pharmacokinetic data in children is through opportunistic studies. Opportunistic studies enroll participants who are already prescribed the drug of interest per standard of care. Ideally, pharmacokinetic samples are also collected at times of routine laboratory blood draws, eliminating the need for study-specific phlebotomy. There are multiple advantages to this approach compared with traditional pharmacokinetic trials, mostly notably that the population of interest can be quickly enrolled. Limitations of opportunistic studies center on the sparse sampling and limited control over timing of samples. As a result, opportunistic studies require larger numbers of children and specialized expertise in modeling.

The Pediatric Trials Network11 has been at the forefront of pediatric drug research. The Pediatric Trials Network is a contract sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development through the Best Pharmaceuticals for Children Act that is tasked with coordinating efforts and creating the infrastructure to conduct safe and effective pediatric clinical drug trials. The investigators in the current study are the leaders of this network and have pioneered pediatric modeling and simulation and innovative approaches to pediatric trial design. In addition to the modeling efforts in this issue of JAMA Pediatrics,8 the Pediatric Trials Network funds the Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) study (NCT04278404) that is currently enrolling children who are prescribed certain drugs per standard of care, including drugs being studied to treat COVID-19. The combined approach of modeling and simulation with confirmatory opportunistic pharmacokinetic trials provides a powerful and efficient way to determine optimal dosing in children during emergency situations such as the current COVID-19 pandemic.

Back to top
Article Information

Corresponding Author: Kevin M. Watt, MD, PhD, Division of Clinical Pharmacology, University of Utah, 274 Chipeta Way, Salt Lake City, UT 84108 (kevin.watt@hsc.utah.edu).

Published Online: June 5, 2020. doi:10.1001/jamapediatrics.2020.2435

Conflict of Interest Disclosures: Dr Watt is an investigator in the Pediatric Trials Network and collaborates with investigators on other studies.

References
1.
Frattarelli  DA, Galinkin  JL, Green  TP,  et al; American Academy of Pediatrics Committee on Drugs.  Off-label use of drugs in children.   Pediatrics. 2014;133(3):563-567. doi:10.1542/peds.2013-4060PubMedGoogle ScholarCrossref
2.
Kearns  GL, Abdel-Rahman  SM, Alander  SW, Blowey  DL, Leeder  JS, Kauffman  RE.  Developmental pharmacology: drug disposition, action, and therapy in infants and children.   N Engl J Med. 2003;349(12):1157-1167. doi:10.1056/NEJMra035092PubMedGoogle ScholarCrossref
3.
Woodcock  J, Woosley  R.  The FDA critical path initiative and its influence on new drug development.   Annu Rev Med. 2008;59:1-12. doi:10.1146/annurev.med.59.090506.155819PubMedGoogle ScholarCrossref
4.
Hwang  TJ, Orenstein  L, Kesselheim  AS, Bourgeois  FT.  Completion rate and reporting of mandatory pediatric postmarketing studies under the US Pediatric Research Equity Act.   JAMA Pediatr. 2019;173(1):68-74. doi:10.1001/jamapediatrics.2018.3416PubMedGoogle ScholarCrossref
5.
Grimstein  M, Yang  Y, Zhang  X,  et al.  Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. Food and Drug Administration’s Office of Clinical Pharmacology.   J Pharm Sci. 2019;108(1):21-25. doi:10.1016/j.xphs.2018.10.033PubMedGoogle ScholarCrossref
6.
Leong  R, Vieira  ML, Zhao  P,  et al.  Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials.   Clin Pharmacol Ther. 2012;91(5):926-931. doi:10.1038/clpt.2012.19PubMedGoogle ScholarCrossref
7.
Maharaj  AR, Edginton  AN.  Physiologically based pharmacokinetic modeling and simulation in pediatric drug development.   CPT Pharmacometrics Syst Pharmacol. 2014;3:e150. doi:10.1038/psp.2014.45PubMedGoogle Scholar
8.
Maharaj  A, Wu  H, Hornik  CP,  et al; the Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee.  Simulated assessment of pharmacokinetically guided dosing for investigational treatments of pediatric patients with coronavirus disease 2019.   JAMA Pediatr. Published online June 5, 2020. doi:10.1001/jamapediatrics.2020.2422Google Scholar
9.
Vinks  AA, Emoto  C, Fukuda  T.  Modeling and simulation in pediatric drug therapy: application of pharmacometrics to define the right dose for children.   Clin Pharmacol Ther. 2015;98(3):298-308. doi:10.1002/cpt.169PubMedGoogle ScholarCrossref
10.
Yao  X, Ye  F, Zhang  M,  et al.  In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).   Clin Infect Dis. 2020;ciaa237. doi:10.1093/cid/ciaa237PubMedGoogle Scholar
11.
Pediatric Trials Network. Accessed May 28, 2020. https://pediatrictrials.org/
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×